Cardior Pharmaceuticals GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cardior.de
Clinical Trials
6
Active:3
Completed:2
Trial Phases
2 Phases
Phase 1:4
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Phase 2
2 (33.3%)Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
Phase 2
Withdrawn
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Cardior Pharmaceuticals GmbH
- Registration Number
- NCT05953831
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
Phase 2
Completed
- Conditions
- Myocardial Infarction, AcuteHeart Failure, Left Sided
- Interventions
- Drug: Placebo to CDR132L
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Cardior Pharmaceuticals GmbH
- Target Recruit Count
- 294
- Registration Number
- NCT05350969
- Locations
- 🇨🇿
Institut klinicke a experimentalni mediciny, Praha, Czechia
🇨🇿Všeobecná fakultní nemocnice v Praze, Praha, Czechia
🇩🇪St. Marien-Krankenhaus Ahaus, Ahaus, Germany
Clinical Study to Assess Safety, PK and PD Parameters of CDR132L
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Cardior Pharmaceuticals GmbH
- Target Recruit Count
- 28
- Registration Number
- NCT04045405
- Locations
- 🇬🇧
Richmond Pharmacology Ltd., 1A Newcomen Street, London Bridge, London, United Kingdom
News
No news found